Unknown PHASE2 INTERVENTIONAL 1-arm NCT06198465

Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma

Perioperative Adebrelimab and Chemotherapy in Esophageal and Esophagogastric Junction Carcinoma: a Prospective, Open-label, Single-center Clinical Study

Sponsor: Xijing Hospital

Conditions Adebrelimab Esophageal Cancer Perioperative Period

Interventions adebrelimab,Paclitaxel,Lobaplatin,Fluorouracil

Updated 4 times since 2024 Last updated: Jan 8, 2024 Started: Mar 30, 2024 Primary completion: Dec 30, 2024 Completion: Dec 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Adebrelimab and Esophageal Cancer and is currently ongoing. Xijing Hospital leads this study, which shows 4 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Feb 2026 — Present [monthly]

Unknown PHASE2

Status: Not Yet Recruiting → Unknown
Sep 2024 — Feb 2026 [monthly]

Not Yet Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Not Yet Recruiting PHASE2
Feb 2024 — Jul 2024 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Xijing Hospital

Data source: Xijing Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Xi'an, China